# Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

> **NCT03794973** · PHASE2 · WITHDRAWN · sponsor: **Tolerion, Inc.**

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** TOL-3021
- **OTHER:** TOL-3021 Placebo

## Key facts

- **NCT ID:** NCT03794973
- **Lead sponsor:** Tolerion, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-14
- **Primary completion:** 2021-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Modification to Clinical Development Plan
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794973, "Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03794973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*